Cancer Biotherapy: Review and Prospect

Overview

Journal Clin Exp Med

Specialty General Medicine

Date 2024 May 27

PMID 38801637

Authors

Qi Liu

Hu Ma

Affiliations

Soon will be listed here.

Abstract

Malignant tumors pose a grave threat to the quality of human life. The prevalence of malignant tumors in China is steadily rising. Presently, clinical interventions encompass surgery, radiotherapy, and pharmaceutical therapy in isolation or combination. Nonetheless, these modalities fail to completely eradicate malignant tumor cells, frequently leading to metastasis and recurrence. Conversely, tumor biotherapy has emerged as an encouraging fourth approach in preventing and managing malignant tumors owing to its safety, efficacy, and minimal adverse effects. Currently, a range of tumor biotherapy techniques are employed, including gene therapy, tumor vaccines, monoclonal antibody therapy, cancer stem cell therapy, cytokine therapy, and adoptive cellular immunotherapy. This study aims to comprehensively review the latest developments in biological treatments for malignant tumors.

Citing Articles

A new potential strategy for cutaneous squamous cell carcinoma treatment by generating serum-based antibodies from tumor-exposed mice.

Liu Z Elife. 2024; 13.

PMID: 39405093 PMC: 11479585. DOI: 10.7554/eLife.95678.

References

MacLeod K . Tumor suppressor genes. Curr Opin Genet Dev. 2000; 10(1):81-93. DOI: 10.1016/s0959-437x(99)00041-6. View

Song Z, Guo C, Li Y, Tan B, Fan L, Xiao J . Enhanced antitumor effects of a dendritic cell vaccine transfected with gastric cancer cell total RNA carrying the 4-1BBL gene in vitro. Exp Ther Med. 2012; 3(2):319-323. PMC: 3438532. DOI: 10.3892/etm.2011.394. View

Kawamura K, Bahar R, Namba H, Seimiya M, Takenaga K, Hamada H . Bystander effect in uracil phosphoribosyltransferase/5-fluorouracil-mediated suicide gene therapy is correlated with the level of intercellular communication. Int J Oncol. 2000; 18(1):117-20. DOI: 10.3892/ijo.18.1.117. View

Rosenberg S . IL-2: the first effective immunotherapy for human cancer. J Immunol. 2014; 192(12):5451-8. PMC: 6293462. DOI: 10.4049/jimmunol.1490019. View

Liu S, Song W, Liu F, Zhang J, Zhu S . Antitumor efficacy of VP22-CD/5-FC suicide gene system mediated by lentivirus in a murine uveal melanoma model. Exp Eye Res. 2018; 172:144-151. DOI: 10.1016/j.exer.2018.04.009. View

Leleux J, Albershardt T, Parsons A, Ter Meulen J, Berglund P . ZVex™, a dendritic-cell-tropic lentivector, primes protective antitumor T cell responses that are significantly boosted using heterologous vaccine modalities. Vaccine. 2020; 38(41):6367-6373. DOI: 10.1016/j.vaccine.2020.08.003. View

Sarnaik A, Hamid O, Khushalani N, Lewis K, Medina T, Kluger H . Lifileucel, a Tumor-Infiltrating Lymphocyte Therapy, in Metastatic Melanoma. J Clin Oncol. 2021; 39(24):2656-2666. PMC: 8376325. DOI: 10.1200/JCO.21.00612. View

Daher M, Rezvani K . Next generation natural killer cells for cancer immunotherapy: the promise of genetic engineering. Curr Opin Immunol. 2018; 51:146-153. PMC: 6140331. DOI: 10.1016/j.coi.2018.03.013. View

Carreno B, Magrini V, Becker-Hapak M, Kaabinejadian S, Hundal J, Petti A . Cancer immunotherapy. A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells. Science. 2015; 348(6236):803-8. PMC: 4549796. DOI: 10.1126/science.aaa3828. View

10.

Xiao L, Cen D, Gan H, Sun Y, Huang N, Xiong H . Adoptive Transfer of NKG2D CAR mRNA-Engineered Natural Killer Cells in Colorectal Cancer Patients. Mol Ther. 2019; 27(6):1114-1125. PMC: 6554529. DOI: 10.1016/j.ymthe.2019.03.011. View

11.

Diao L, Liu M . Rethinking Antigen Source: Cancer Vaccines Based on Whole Tumor Cell/tissue Lysate or Whole Tumor Cell. Adv Sci (Weinh). 2023; 10(22):e2300121. PMC: 10401146. DOI: 10.1002/advs.202300121. View

12.

Dong H, Li M, Yang C, Wei W, He X, Cheng G . Combination therapy with oncolytic viruses and immune checkpoint inhibitors in head and neck squamous cell carcinomas: an approach of complementary advantages. Cancer Cell Int. 2023; 23(1):1. PMC: 9814316. DOI: 10.1186/s12935-022-02846-x. View

13.

Malhotra J, Jabbour S, Aisner J . Current state of immunotherapy for non-small cell lung cancer. Transl Lung Cancer Res. 2017; 6(2):196-211. PMC: 5420529. DOI: 10.21037/tlcr.2017.03.01. View

14.

Kohler G, Milstein C . Continuous cultures of fused cells secreting antibody of predefined specificity. Nature. 1975; 256(5517):495-7. DOI: 10.1038/256495a0. View

15.

Yarchoan M, Johnson 3rd B, Lutz E, Laheru D, Jaffee E . Targeting neoantigens to augment antitumour immunity. Nat Rev Cancer. 2017; 17(4):209-222. PMC: 5575801. DOI: 10.1038/nrc.2016.154. View

16.

Chen J, Shen Z, Jiang X, Huang Z, Wu C, Jiang D . Preclinical evaluation of IAP0971, a novel immunocytokine that binds specifically to PD1 and fuses IL15/IL15R complex. Antib Ther. 2023; 6(1):38-48. PMC: 9847340. DOI: 10.1093/abt/tbac031. View

17.

Jain S, Clark J . Ipilimumab for the treatment of melanoma. Melanoma Manag. 2018; 2(1):33-39. PMC: 6094709. DOI: 10.2217/mmt.14.25. View

18.

Walcher L, Kistenmacher A, Suo H, Kitte R, Dluczek S, Strauss A . Cancer Stem Cells-Origins and Biomarkers: Perspectives for Targeted Personalized Therapies. Front Immunol. 2020; 11:1280. PMC: 7426526. DOI: 10.3389/fimmu.2020.01280. View

19.

Ongaro T, Matasci M, Cazzamalli S, Gouyou B, De Luca R, Neri D . A novel anti-cancer L19-interleukin-12 fusion protein with an optimized peptide linker efficiently localizes in vivo at the site of tumors. J Biotechnol. 2018; 291:17-25. DOI: 10.1016/j.jbiotec.2018.12.004. View

20.

Tamura R, de Luna I, Lana M, Strauss B . Improving adenoviral vectors and strategies for prostate cancer gene therapy. Clinics (Sao Paulo). 2018; 73(suppl 1):e476s. PMC: 6097088. DOI: 10.6061/clinics/2018/e476s. View